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Abstract
Background: The objective was to understand the influence of Survivin plasmid with short hairpin
RNA (shRNA) on the cell cycle, invasion, and the silencing effect of Survivin gene in the SW480 cell
of colorectal carcinoma.
Methods:  A eukaryotic expression vector, PGCH1/Survivin shRNA, a segment sequence of
Survivin as target, was created and transfected into colorectal carcinoma cell line SW480 by the
non-lipid method. The influence on the Survivin protein was analyzed by Western blotting, while
the cell cycle, cell apoptosis were analyzed by flow cytometry, and invasion of the cell was analyzed
by Transwell's chamber method.
Results: After the transfection of PGCH1/Survivin shRNA, the expression of Survivin protein in
SW480 cells was dramatically decreased by 60.68%, in which the cells were stopped at G2/M phase,
even though no apoptosis was detected. The number of transmembranous cells of the
experimental group, negative control group, and blank control group were 14.46 ± 2.11, 25.12 ±
8.37, and 25.86 ± 7.45, respectively (P <0.05).
Conclusion: Survivin shRNA could significantly reduce the expression of Survivin protein and
invasion of SW480 cells. Changes in cell cycle were observed, but no apoptosis was induced.
1. Introduction
Colorectal cancer is one of the most commonly seen,
malignant tumors in human, and the incidence rate is
gradually increasing year by year. In United States, it was
the second reason leading to death caused by malignant
tumor, and the number of annual incidence had reached
135,000 people. Currently, combined therapy, which pri-
marily focused on surgical removal, is employed for most
cases of colorectal cancer. However, the cost for this com-
bined treatment is relatively higher and more side effects
existed. Also, the primary reasons for failed therapy are the
localized reoccurrence and hepatic metastasis. Therefore,
to cure patients in time, prevention and early detection of
localized reoccurrence and hepatic metastasis, as well as
screening of high-risk patients and prediction of reoccur-
rence and metastasis, have significant meaning in improv-
ing patient's life quality and survival rate. With the
development of molecular biology and genetic engineer-
ing, the gene therapy is the research focus for prevention
and treatment of tumor. Currently, gene therapies for
tumor include gene replacement, antisense nucleic acid
technique, cytokine gene therapy, and RNA interference
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technique mostly focused in recent years. RNA interfer-
ence is the most effective gene silencing technique cur-
rently, while being simple, effective, and specific as its
advantages. It primarily uses nuclease to cut double-
stranded RNA (dsRNA) into 21 to 25 nt of small interfer-
ing RNA, also known as siRNA. The siRNA, based on the
principle of base pairing, could specifically recognize and
cleave the homogenous target mRNA molecule, to achieve
the silencing effect. The short hairpin RNA (shRNA) could
automatically be processed to become siRNA to silence
gene, and it was proven to be more stable than siRNA. Sur-
vivin is a member of apoptotic inhibitory protein, and is
selectively expressed in tumor tissues, especially with high
expression in colorectal cancer, rather than in normal
mature tissues. [1,2]. Survivin gene is an ideal target site
for treating colorectal tumor [3]. In this study, a plasmid
with expression of shRNA, which targeted specifically the
Survivin gene, was created and used to transfect SW480
cells. The influence of Survivin shRNA on the cell cycle
and the invasion ability of SW480 cells of colorectal carci-
noma, as well as its efficacy in silencing Survivin gene,
were analyzed in this paper.
2. Materials and methods
Reagents and equipments
The pGCsilencer™H1/Neo/GFP/RNAi expression vector
was purchased form Genechem Company. Restriction
endonuclease Hind and BamH1 were from Qiagen Com-
pany. DMEM culture media were from GIBCO Company.
Fetal bovine serum was purchased from Tianjing. Survivin
polyclonal antibodies were purchased from Santa Cruz
Company. FuGENE6, non-lipid transfection reagent, was
product of Roche Company. Human colon carcinoma cell
line SW480 was from Nanjing Kaiji Biology. Transwell's
chamber (8 μm of pore diameter) was product of Milli-
pore Company. Artificial basal membrane known as
Matrigel was purchased from BD Company.
Design of target sequence of shRNA
Survivin gene sequence came from GenBank
(NM001168), with the size of 999 bp. Usage of
GeneChem™siRNA, based on the design principle for
siRNA, 19nt target sequence of siRNA was selected as tem-
plate: GGCTGGCTTCATCCACTGC (86–104). By BLAST
analysis, it was no homogy with other coding sequences
in human. The 5'-end of the sequence corresponded with
the cut-off point for BamHI enzyme, while the 3'-end,
which had the T6 sequence, corresponded to the cutting
site for Hind III enzyme. A ring sequence of 9 base pairs
existed between the sense and antisense strands (TTCAA-
GAGA). The pGCsi-H1/Neo/GFP/NON RNAi vector was
used as negative control, which did not interfere the stud-
ied intrinsic gene.
The construction of pGCH1/Survivin shRNA expression 
plasmid
Two strands of oligonucleotides would undergo anneal-
ing, double enzyme-cut by restriction endonuclease Hind
and BamH1, ligation, and transformation, as well as the
PCR process, to identify positive clones. The constructed
pGCH1/Survivin shRNA expression plasmid would be
sequencing by Shanghai Invitrogen Biotechnology Com-
pany.
Cell culture and transfection
Grouping
Blank control group, negative control group, and specific
interference group were set up in this experiment.
Transfection
The human colon cancer cell line SW480 was recovered in
water bath and was cultured in DMEM media with 10%
fetal bovine serum, 100 U/ml penicillin, and 100 μg/ml
streptomycin at 37°C incubator containing 5% CO2. One
day before the transfection, cells in logarithmic growth
phase were digested by 0.25% trypsin. Cells were seeded
into the 6-well plate with 3 × 105 cells per hole. After the
cells adhered to the bottom, they were transfected by fol-
lowing the instructions of the test kit.
Measurement Survivin protein level in each group by 
Western blotting
After 48 hours of transfection, cells and supernatant of
each group would be collected. Proteins were extracted
after break-down of cells by SDS boiling method. Proteins
were quantified by Bradford method. 40 μg of protein
underwent SDS-PAGE and was transferred to PVDF mem-
brane afterward. It was then sealed at room temperature
for 2 hours. The primary antibodies, rabbit anti-human
Survivin antibodies, were added at a ratio of 1:1000, and
incubated overnight at 4°C. The membrane was washed
with PBS. Then, the secondary antibodies, goat anti-rabbit
IgG/HRP antibodies, were added at a ratio of 1:4000, and
incubated at room temperature for 2 hours. The mem-
brane was washed three times and reacted with chemilu-
minescent agent for 5 minutes. It was then ECL tabletting,
exposed, and displayed.
Measurment the cell cycle and apoptosis of SW480 cells by 
flow cytometry
After 48 hours of transfection, cells of each group were
digested by Trypsin. Afterward, pre-cooled PBS in 4°C was
added to prepare it into single-cell suspension and centri-
fuged for 10 minutes at 1000 rpm. The supernatant was
discarded. 0.5 ml of pre-cooled 70% alcohol was then
added and the solution was left in 4°C refrigerator over-
night. The solution was then centrifuged again for 10 min-
utes at 1000 rpm and the supernatant was discarded. The
remaining cells were then re-suspended by PBS and centri-Journal of Experimental & Clinical Cancer Research 2008, 27:20 http://www.jeccr.com/content/27/1/20
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fuged. The supernatant was discarded. Afterward 500 μl of
PBS was added to re-suspend it again. 500 μl PI staining
solution was added. It was left on ice, and incubated away
from light for 30 minutes. The cell cycle and apoptosis
were then measured by flow cytometry.
Analysis of cell invasion ability
On the side, facing the upper chamber, of the covering
membrane of the Transwell's chamber, 30 μg Matrigel was
applied. The lower chamber was added with 400 ul of
conditioned medium from normal fibroblasts NIH3T3
cells(please note to avoid production of air bubbles
between the culture media and the small chamber). The
upper levels were respectively added with 100 ul of single-
cell suspension (1 × 106) of each group, which was already
transfected for 48 hours.
Cell culturing
Placed in an incubator of 37°C and 5% CO2, cells were
cultured for 48 hours.
Statistics of results
The small chamber was taken out and the non-migrated
cells and Matrigel in the upper room of chamber were
carefully removed by wool. It was then fixed at constant
temperature for 30 minutes with 90% ethanol, and
stained with 0.1% crystal violet solution for 20 minutes. It
was placed under upright microscope for observation and
photography. Randomly, 10 visual fields were selected
and counted of penetrating cells. The average was calcu-
lated, in which the relative number of transmembrane
cells represented the invasion ability of tumor cells. For
each specimen, it was repeated twice, with the experiment
also repeated for three times. Invasion inhibition rate = (1
– number of penetrating cells in experimental group/
number of penetrating cells in control group) × 100%.
Statistical analysis
The SPSS 13.0 software was used to establish database for
statistical analysis. The number of transmembrane cells
was represented in form of   ± s. The inter-group differ-
ences were using single-factor variance analysis, where p
value less than 0.05 was considered as statistical signifi-
cance.
3. Results
The construction of pGCH1/Survivin shRNA expression 
plasmid
The sequencing result showed the shRNA coding
sequence in recombinant plasmid was exactly coincidence
with our designed target Survivin's nucleic acid sequence.
It suggested that the construction of recombinant plasmid
pGCsiRNA-Survivin was a success (Figure 1). After the
colorectal cancer cell line SW480 was transfected with the
plasmid, cells showed green luminescence, suggesting the
correct expression of pGCH1/Survivin shRNA (Figure 2).
The influence of pGCH1/Survivin shRNA on the Survivin 
protein expression in SW480 cells
When analyzed by Western blot, the protein expression
levels of the pGCsiRNA-Survivin specific interference
group, the negative control group, and the blank control
group were 11.32%, 24.08%, and 28.79%, respectively.
When the specific interference group was compared to the
blank control group, the expression level of Survivin pro-
tein was significantly reduced (p < 0.05), with an inhibi-
tory rate of 60.68%. In the comparison between the
negative plasmid group and the blank control group, the
expression of Survivin had no obvious change (p > 0.05)
(Figure 3).
x
The sequencing results of recombinant plasmid Figure 1
The sequencing results of recombinant plasmid.
Figure 1. The sequencing results of recombinant plasmidJournal of Experimental & Clinical Cancer Research 2008, 27:20 http://www.jeccr.com/content/27/1/20
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The influence of pGCH1/Survivin shRNA on the cell cycle 
and the apoptosis of SW480 cells
In the comparison of the specific interference group trans-
fected with pGCsiRNA-Survivin and the blank control
group, the percentage of cells in G2/M phase was
increased in the specific interference group (P < 0.05). In
the comparison of the negative control group and the
blank control group, there was no difference seen in the
cell cycle. There were no apoptotic peaks in all three
groups (Figure 4).
The invasion ability of SW480 cells tested by Transwell's 
chamber
The ability of tumor cells to permeate the chambers was
significantly reduced in the specific interference group
transfected with pGCsiRNA-Survivin. It could be specu-
lated that pGCsi-Survivin could reduce the invasion abil-
ity of SW480 cells of colorectal cancer. The inhibitory rate
was 44.08% (Figure 5) (See table 1 in additional file 1).
4. Discussion
Colorectal cancer has the characteristics of powerful inva-
sion ability and early metastatic property, which are the
primary reasons for failure in therapy. To research the
molecular mechanisms for invasion and metastasis of
colorectal tumor cells, as well as finding treatment target
site, has significant meaning for improvement the prog-
nostic outcome. Currently, researches that involved the
gene and cytokines such as CD44 and E-cadherin, which
were related to tumor metastasis, revealed that the expres-
sion level was closely related to the metastatic ability. In
the metastatic process, tumor cells would have to fall off
from primary lesion and penetrate the basal membrane.
Tumor cells had characteristics of being infiltrative, in
which it could penetrate the basal membrane to achieve
infiltrative metastasis. In this study, the ability of cells to
penetrate Matrigel was used as an indicator to reflect the
invasion ability.
Survivin gene is generally highly expressed in human
colorectal tumor cells, and relates to the decrease in the
apoptotic index, shortened the overall survival rate, poor
prognosis and the increase in recurrence rate [4-6]. There-
fore, Survivin had become an important target for tumor
therapy, in which most methods involved the reduction
of Survivin expression as a way to treat tumor. The mech-
Measurement the cell cycle and apoptosis by FCM Figure 4
Measurement the cell cycle and apoptosis by FCM.
     
      blank  control  group                           negative  control  group 
     specific  interference  group 
Figure 4. Measurement the cell cycle and apoptosis by FCM
Observation of the expression of green luminescent protein  in SW480 cells transfected with pGCH1/Survivin shRNA  under fluorescent microscope Figure 2
Observation of the expression of green luminescent protein 
in SW480 cells transfected with pGCH1/Survivin shRNA 
under fluorescent microscope.
Figure 2. Observation of the expression of green luminescent protein in SW480 cells 
transfected with pGCH1/Survivin shRNA under fluorescent microscope
The expression level of Survivin protein of transfected cells Figure 3
The expression level of Survivin protein of transfected cells.
    S u r v i v i n  
                 1         2            3
Figure 3. The expression level of Survivin protein of transfected cells. 1 specific 
interference group. 2 negetive control group.3 blank control group
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anism mostly was inhibiting the expression of Survivin to
promote apoptosis of tumor cells, and thus, to inhibit the
proliferation of tumor cells [7,8]. In this study, pGCH1/
Survivin shRNA was used to transfect colorectal tumor cell
SW480, to reduce the expression of Survivin protein.
Analysis by flow cytometry revealed that cells were
delayed at G2/M phase, but there was no increase in apop-
tosis, which were similar to other reports [10]. It suggested
that Survivin shRNA could, through other mechanisms
other than the apoptotic pathway, inhibit the biological
activities of tumor. After the expression of Survivin was
down-regulated, the invasion ability of SW480 cells was
greatly reduced, suggesting that the expression of Survivin
was related to the infiltrative property of colorectal tumor
cells. The involving mechanism was probably that
changes in microtubule structures occurred when cells
were delayed at G2/M phase, which further reduced the
cellular elasticity coefficient and thus the reduce in inva-
sion ability [11]. In addition, there were reports that the
inhibition of Survivin expression could decrease the
expression of tumor angiogenesis factor, and further pre-
vented the invasion of SW480 cells [9,12,13].
In this research, it was discovered that the inhibition of
Survivin expression could reduce the invasion ability of
colorectal tumor cells, suggesting that Survivin gene was
related to the tumor metastasis. By RNA interference
method to reduce the expression of Survivin, the metasta-
sis of tumor could be inhibited as well. This would pro-
vide evidences for further research into the characteristics
of Survivin and RNA interference in the aspect of tumor
genetic therapy. The interaction between the metastasis of
tumor and metastasis-related factors was extremely com-
plicated, and there were still many unknown involving
mechanisms, which required further investigation.
Note
Table 1. The number of invasive cells of each group.
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The invasion test of SW480 cells Figure 5
The invasion test of SW480 cells.
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